

Lara A Kahale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9319750/publications.pdf>

Version: 2024-02-01

50
papers

2,938
citations

304368

22
h-index

243296

44
g-index

50
all docs

50
docs citations

50
times ranked

3684
citing authors

#	ARTICLE	IF	CITATIONS
1	Parenteral anticoagulation in ambulatory patients with cancer. The Cochrane Library, 2023, 2023, CD006652.	1.5	42
2	Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. The Cochrane Library, 2023, 2023, CD006650.	1.5	65
3	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Advances, 2021, 5, 927-974.	2.5	431
4	PRISMA flow diagrams for living systematic reviews: a methodological survey and a proposal. F1000Research, 2021, 10, 192.	0.8	12
5	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1108-1123.	2.9	339
6	Using Parallel Streams of Evidence to Inform Guideline Development: The Case of the 2021 American College of Rheumatology Management of Rheumatoid Arthritis Guideline. ACR Open Rheumatology, 2021, 3, 629-635.	0.9	4
7	Methods and guidance on conducting, reporting, publishing and appraising living systematic reviews: a scoping review protocol. F1000Research, 2021, 10, 802.	0.8	8
8	Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents. The Cochrane Library, 2021, 2021, CD014739.	1.5	4
9	Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. The Cochrane Library, 2021, 2021, CD006466.	1.5	2
10	Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. The Cochrane Library, 2021, 2021, CD006649.	1.5	4
11	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematology, the, 2020, 7, e746-e755.	2.2	21
12	Potential impact of missing outcome data on treatment effects in systematic reviews: imputation study. BMJ, The, 2020, 370, m2898.	3.0	14
13	<p>Meta-Analyses Proved Inconsistent in How Missing Data Were Handled Across Their Included Primary Trials: A Methodological Survey</p>. Clinical Epidemiology, 2020, Volume 12, 527-535.	1.5	4
14	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1940-1951.	1.9	60
15	Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. The Cochrane Library, 2019, 2019, CD006649.	1.5	26
16	Anticoagulation for people with cancer and central venous catheters. The Cochrane Library, 2019, 2019, CD006468.	1.5	28
17	Anticoagulation for perioperative thromboprophylaxis in people with cancer. The Cochrane Library, 2019, 2019, CD009447.	1.5	15
18	A guidance was developed to identify participants with missing outcome data in randomized controlled trials. Journal of Clinical Epidemiology, 2019, 115, 55-63.	2.4	8

#	ARTICLE	IF	CITATIONS
19	Potentially missing data are considerably more frequent than definitely missing data: a methodological survey of 638 randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 18-31.	2.4	8
20	Methods of conduct and reporting of living systematic reviews: a protocol for a living methodological survey. <i>F1000Research</i> , 2019, 8, 221.	0.8	10
21	Methods of conduct and reporting of living systematic reviews: a protocol for a living methodological survey. <i>F1000Research</i> , 2019, 8, 221.	0.8	12
22	Systematic reviews do not adequately report or address missing outcome data in their analyses: a methodological survey. <i>Journal of Clinical Epidemiology</i> , 2018, 99, 14-23.	2.4	22
23	Extent of physician-pharmaceutical industry interactions in low- and middle-income countries: a systematic review. <i>European Journal of Public Health</i> , 2018, 28, 224-230.	0.1	14
24	Effectiveness of behavioral interventions to reduce the intake of sugar-sweetened beverages in children and adolescents: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2018, 76, 88-107.	2.6	48
25	Body positioning for spontaneously breathing preterm infants with apnoea. <i>The Cochrane Library</i> , 2017, 2017, CD004951.	1.5	15
26	A systematic survey on reporting and methods for handling missing participant data for continuous outcomes in randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2017, 88, 57-66.	2.4	24
27	GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. <i>Journal of Clinical Epidemiology</i> , 2017, 87, 14-22.	2.4	124
28	Living systematic reviews: 4. Living guideline recommendations. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 47-53.	2.4	184
29	Living systematic review: 1. Introduction-the why, what, when, and how. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 23-30.	2.4	406
30	Living systematic reviews: 2. Combining human and machine effort. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 31-37.	2.4	246
31	Living systematic reviews: 3. Statistical methods for updating meta-analyses. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 38-46.	2.4	102
32	Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. <i>The Cochrane Library</i> , 2017, 12, CD006466.	1.5	17
33	A systematic survey of the methods literature on the reporting quality and optimal methods of handling participants with missing outcome data for continuous outcomes in randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2017, 88, 67-80.	2.4	32
34	Association between physicians' interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0175493.	1.1	101
35	Knowledge, Beliefs and Attitudes of Patients and the General Public towards the Interactions of Physicians with the Pharmaceutical and the Device Industry: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0160540.	1.1	33
36	Three challenges described for identifying participants with missing data in trials reports, and potential solutions suggested to systematic reviewers. <i>Journal of Clinical Epidemiology</i> , 2016, 76, 147-154.	2.4	27

#	ARTICLE	IF	CITATIONS
37	Knowledge, beliefs and attitudes of physicians in low and middle-income countries regarding interacting with pharmaceutical companies: a systematic review. BMC Health Services Research, 2016, 16, 57.	0.9	23
38	Handling trial participants with missing outcome data when conducting a meta-analysis: a systematic survey of proposed approaches. Systematic Reviews, 2015, 4, 98.	2.5	48
39	Reporting missing participant data in randomised trials: systematic survey of the methodological literature and a proposed guide. BMJ Open, 2015, 5, e008431.	0.8	35
40	Association Between Perioperative Low-Molecular-Weight Heparin vs Unfractionated Heparin and Clinical Outcomes in Patients With Cancer Undergoing Surgery. JAMA - Journal of the American Medical Association, 2015, 313, 1364.	3.8	5
41	Legislative, educational, policy and other interventions targeting physicians' interaction with pharmaceutical companies: a systematic review. BMJ Open, 2014, 4, e004880-e004880.	0.8	25
42	Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study. Systematic Reviews, 2014, 3, 137.	2.5	13
43	Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. The Cochrane Library, 2014, , CD006650.	1.5	152
44	Anticoagulation for people with cancer and central venous catheters. The Cochrane Library, 2014, , CD006468.	1.5	41
45	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2014, , CD006466.		13
46	Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. The Cochrane Library, 2014, , CD009447.	1.5	32
47	Tailored PRISMA 2020 flow diagrams for living systematic reviews: a methodological survey and a proposal. F1000Research, 0, 10, 192.	0.8	6
48	Tailored PRISMA 2020 flow diagrams for living systematic reviews: a methodological survey and a proposal. F1000Research, 0, 10, 192.	0.8	22
49	Extension of the PRISMA 2020 statement for living systematic reviews (LSRs): protocol. F1000Research, 0, 11, 109.	0.8	9
50	Extension of the PRISMA 2020 statement for living systematic reviews (LSRs): protocol. F1000Research, 0, 11, 109.	0.8	2